title: Hsp90 inhibitors in breast cancer: a systematic review.
abstract: OBJECTIVE
  Pharmacological inhibition of Hsp90 shows great promise in breast cancer treatment. This is the first systematic review to synthesize all available data and to evaluate the efficacy and safety of Hsp90 inhibitors in breast cancer.
  
  
  METHODS
  This study was performed in accordance with the PRISMA guidelines. Eligible articles were identified by a search of MEDLINE and ClinicalTrials.gov databases, using a predefined combination of the terms "breast", "cancer", "Hsp90", "inhibitors".
  
  
  RESULTS
  Overall, 19 articles (190 patients) were eligible. The greatest clinical activity has been observed on the field of HER2-positive metastatic breast cancer. However, accumulating data suggest that Hsp90 inhibitors may play a significant role in the treatment of triple negative and aromatase inhibitor-resistant breast cancer.
  
  
  CONCLUSIONS
  In the last decade, the development of Hsp90 inhibitors has moved forward rapidly; however, no phase III trials have been conducted and none agent has been approved for use in the clinical practice.
authors.affiliation: Department of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Vas Sofias Ave & Lourou Str, Athens 11521, Greece. Electronic address: florazagouri@yahoo.co.uk.
authors.forename: Flora
authors.initials: F
authors.lastname: Zagouri
authors.forename: Theodoros N
authors.initials: TN
authors.lastname: Sergentanis
authors.forename: Dimosthenis
authors.initials: D
authors.lastname: Chrysikos
authors.forename: Christos A
authors.initials: CA
authors.lastname: Papadimitriou
authors.forename: Meletios-Athanassios
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Theodora
authors.initials: T
authors.lastname: Psaltopoulou
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use; D016227:Benzoquinones / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D005998:Glycine; D018840:HSP70 Heat-Shock Proteins / Q000097:blood; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000097:blood; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D047029:Lactams, Macrocyclic / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D012118:Resorcinols / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy*
chemical_list: C528044:5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; C521963:6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine; D000970:Antineoplastic Agents; D001549:Benzamides; D016227:Benzoquinones; D014408:Biomarkers, Tumor; D018840:HSP70 Heat-Shock Proteins; D018841:HSP90 Heat-Shock Proteins; D007191:Indazoles; D007555:Isoxazoles; D047029:Lactams, Macrocyclic; D011725:Pyridines; D012118:Resorcinols; C533237:STA 9090; D014230:Triazoles; C448659:17-(dimethylaminoethylamino)-17-demethoxygeldanamycin; C112765:tanespimycin; C561943:SNX-5422; D000225:Adenine; D005998:Glycine
keywords: Alvespimycin; Breast cancer; Hsp90 inhibitors; Retaspimycin; Tanespimycin